Cancer Stem Cells

Despite current advances in cancer therapy, tumor recurrence and metastases continue to be clinical challenges. A potential new approach to dealing with this is the targeting of a subset of the tumor cell population known as CSC's or Cancer Stem Cells (Stem Cells) .


CSC's are highly tumorigenic, have high metastatic potential and are resistant to conventional cancer therapies.

Cancer Stem Cells May Help Explain Tumor Relapse

In the clonal evolution model, all cells within a malignant tumor have similar tumorigenic activity. In contrast, only a subset of tumor cells, CSCs, have the ability to initiate the tumor. This may help explain why early tumor shrinkage is often poorly predicted for overall survival. While conventional therapies kill most Non-Trunk Cancer Cells resulting in tumor shrinkage, CSCs may remain viable and later restore the tumor, leading to relapse.

References

  1. Li Y, Rogoff H, Keates S, et al. Suppression of cancer relapse and metastasis by inhibiting cancer stemness. Proc Natl Acad Sci U S A. 2015;112(6):1839-1844.
  2. Fanali C, Lucchetti D, Farina M, et al. Cancer stem cells in colorectal cancer from pathogenesis to therapy: controversies and perspectives. World J Gastroenterol. 2014;20(4):923-942.
  3. Botchkina G, Ojima I. Prostate and colon cancer stem cells as a target for anti-cancer drug development. In: Shostak S, ed. Cancer Stem Cells: Theories and Practice. Rijeka, Croatia: InTech; 2011.
  4. Reya T, Morrison S, Clarke M, Weissman I. Stem cells, cancer, and cancer stem cells. Nature. 2001;414(6859):105-111.
  5. Marjanovic N, Weinberg RC, CL. Cell plasticity and heterogeneity in cancer. Clin Chem. 2013;59(1):168-179.
  6. Coart E, Saad E, Shi Q, et al. Trial-level association between response-based endpoints and progression-free/overall survival in 1st-line therapy for metastatic colorectal cancer in the ARCAD database. J Clin Oncol. 2015;33(suppl 3; abstr 666).
  7. Zabor E, Heller G, Schwartz L, Chapman P. Correlating surrogate endpoints with overall survival at the individual patient level in BRAFV600E-mutated metastatic melanoma patients treated with vemurafenib. Clin Cancer Res. 2016;22(6):1341-1347.